Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
4.345 USD -1.03% Intraday chart for Achieve Life Sciences, Inc. -2.58% +5.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Achieve Life Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting CI
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Achieve Life Sciences Agrees on Safety Exposure Data for Smoking Cessation Medication as Part of NDA MT
Top Midday Decliners MT
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1% MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $18 From $21, Maintains Outperform Rating MT
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket MT
Top Premarket Decliners MT
Transcript : Achieve Life Sciences, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Achieve Life Sciences, Inc.(NasdaqCM:ACHV) added to S&P Global BMI Index CI
Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting CI
Transcript : Achieve Life Sciences, Inc., Q2 2023 Earnings Call, Aug 15, 2023
Achieve Life Sciences, Inc. Announces Positive Topline Results from A Second Phase 3 ORCA-3 Trial CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association CI
Achieve Life Sciences Files for Potential Secondary Offering MT
Achieve Life Sciences Inc Provides Information to Shareholders CI
Lake Street Adjusts Price Target on Achieve Life Sciences to $19 From $22, Maintains Buy Rating MT
Transcript : Achieve Life Sciences, Inc. - Special Call
Achieve Life Sciences Reports Positive Topline Data From Trial of Cytisinicline; Shares Rise Pre-Bell MT
Chart Achieve Life Sciences, Inc.
More charts
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.345 USD
Average target price
19.71 USD
Spread / Average Target
+353.72%
Consensus
  1. Stock Market
  2. Equities
  3. ACHV Stock
  4. News Achieve Life Sciences, Inc.
  5. Sector Update: Health Care Stocks Decline Late Afternoon